post-marketing surveillance raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-24 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
There is however a marked decrease in hypertrophy for "very slow" durations greater than 10 s. There are similar hypertrophic effects for 50-60% 1RM loads with a slower 3/0/3/0 tempo and 80-90% 1RM loads with a faster 1/1/1/0 tempo. It may be beneficial for both hypertrophy and strength to use fast, short concentric phases and slower, longer eccentric phases. Research has not yet isolated the effects of concentric and eccentric durations, or tested a wide variety of exercises and populations.
== Cost == In Canada, PET scan funding varies by province. In Ontario, as of October 2025, there is no charge to the patient for any PET scans funded as part of the PET Scans Ontario Program. The program funds routine PET services for indications where sufficient evidence exists that the scan benefits the patient and offers advantages over other imaging tests. In the United States, PET scan costs vary significantly by location, facility type, and insurance status. According to Medicare's 2026 payment data, a whole-body PET scan has a national average total cost of $872, with the patient paying approximately $174 after Medicare coverage. In the United Kingdom, the National Health Service provides PET-CT scans free at point of use for eligible patients. In Australia, Medicare subsidies are available for eligible PET services.
Fluoroscopy and angiography are special applications of X-ray imaging, in which a fluorescent screen and image intensifier tube is connected to a closed-circuit television system. This allows real-time imaging of structures in motion or augmented with a radiocontrast agent. Radiocontrast agents are usually administered by swallowing or injecting into the body of the patient to delineate anatomy and functioning of the blood vessels, the genitourinary system, or the gastrointestinal tract (GI tract). Two radiocontrast agents are presently in common use. Barium sulfate (BaSO4) is given orally or rectally for evaluation of the GI tract. Iodine, in multiple proprietary forms, is given by oral, rectal, vaginal, intra-arterial, or intravenous routes. These radiocontrast agents strongly absorb or scatter X-rays, and in conjunction with the real-time imaging, allow demonstration of dynamic processes, such as peristalsis in the digestive tract or blood flow in arteries and veins. Iodine contrast may also be concentrated in abnormal areas more or less than in normal tissues and make abnormalities (tumors, cysts, inflammation) more conspicuous. Additionally, in specific circumstances, air can be used as a contrast agent for the gastrointestinal system, and carbon dioxide can be used as a contrast agent in the venous system; in these cases, the contrast agent attenuates the X-ray radiation less than the surrounding tissues.
Sources: en.wikipedia.org
People need to have a driving licence to drive on a road, and there is a common system of recognition around the EU. For delivery vehicle workers, the Road Transport Regulation 2006 limits daily driving time to 9 hours a day, a maximum of 56 hours a week, and requires at least a 45-minute break after 4+1⁄2 hours. Drivers may also not be paid according to distance travelled if this would endanger road safety. Taxi enterprises are usually regulated separately in each member state, and the attempts of the app-based firm Uber to evade regulation by arguing it was not a "transport service" rather than an "Information Society Service" failed. Most bus networks are publicly owned or procured, but there are common rights. If buses are delayed in journeys over 250 kilometres, the Bus Passenger Rights Regulation 2011 entitles passengers to compensation. Under article 19, a delay over two hours must result in compensation of 50% of the ticket price, as well as rerouting and reimbursement. Article 6 says 'Carriers may offer contract conditions that are more favourable for the passenger', although it is not clear many take up this option. Article 7 says member states cannot set maximum compensation for death or injury lower than €220,000 per passenger or €1200 per item of luggage. There is not yet a requirement for the major bus, delivery, taxi enterprises to electrify their fleets even though this would create the fastest reduction of emissions and would be cheaper for business in total operating costs.
Dermatomyositis (DM) is a group of systemic autoimmune inflammatory diseases primarily affecting the skin and skeletal muscles. Its symptoms are generally a skin rash and worsening muscle weakness over time. These may occur suddenly or develop over months. Other symptoms may include weight loss, fever, lung inflammation, or light sensitivity. Complications may include calcium deposits in muscles or skin. Distinct myositis-specific autoantibodies (MSA) define clinically and pathologically distinct DM subtypes, each associated with characteristic disease manifestations, prognosis, and treatment response. Eighty percent of adults and sixty percent of children with juvenile dermatomyositis have a MSA. These autoantibodies, produced by locally infiltrating plasma cells, can enter various cell types and disrupt the function of their target autoantigens, inducing cellular damage and inflammation that directly drive disease pathogenesis. Dermatomyositis may develop as a paraneoplastic syndrome associated with several malignancies, in which tumors harbor genetic alterations, including somatic mutations, in genes encoding the specific autoantigens targeted by the patient's corresponding autoantibodies. It is known to be associated with several viruses, especially coxsackievirus, but no definitive causal link has been found. Diagnosis is typically based on some combination of symptoms, blood tests, electromyography, and muscle biopsies.
=== Tricyclic antidepressant === Tricyclic antidepressants (TCAs) have a different side effect profile than SSRIs. In a study of inpatients the tricyclic antidepressant amitriptyline, in particular, appears to be more effective.
Sources: en.wikipedia.org
=== Rehabilitation and exercise === Cardiac rehabilitation benefits many who have experienced myocardial infarction, even if there has been substantial heart damage and resultant left ventricular failure. It should start soon after discharge from the hospital. The program may include lifestyle advice, exercise, social support, as well as recommendations about driving, flying, sports participation, stress management, and sexual intercourse. Returning to sexual activity after myocardial infarction is a major concern for most patients, and is an important area to be discussed in the provision of holistic care. In the short-term, exercise-based cardiovascular rehabilitation programs may reduce the risk of a myocardial infarction, reduces a large number of hospitalizations from all causes, reduces hospital costs, improves health-related quality of life, and has a small effect on all-cause mortality. Longer-term studies indicate that exercise-based cardiovascular rehabilitation programs may reduce cardiovascular mortality and myocardial infarction.
== Early life and education == Sur did his early schooling at the St. Joseph's Collegiate School, Allahabad. He received a Bachelor of Technology degree in electrical engineering from the Indian Institute of Technology in Kanpur (IIT Kanpur) in 1974, and Master of Science and PhD degrees in electrical engineering in 1975 and 1978, respectively, from Vanderbilt University in Nashville. After postdoctoral research at Stony Brook University, he was appointed to the faculty of Yale University School of Medicine in 1983.
===== Historical ===== Spider silk is one of the earliest known dermal patches. Primarily used for wound binding, the glycoprotein adhesive found on the capture spiral silk, as well as the protein structure of the fiber itself, has mild antibacterial properties. The silk, acting as a local antiseptic, reduced the rate of sepsis and chronic illness. The silk's viscoelastic properties and high tensile strength and toughness aided wound healing in a way similar to surgical tape.
The Parliamentary Commission on Standards finds that Lord Waheed Alli committed four minor breaches in the register of members' interests. 24 October – Chancellor Rachel Reeves announces the UK government is to change its self-imposed debt rules in order to make an extra £50bn available for spending at the forthcoming budget. Lee Waters announces he will step down from the Senedd at the 2026 election. 26 October – Commonwealth leaders agree the "time has come" for a conversation about reparations for the slave trade, despite the UK's wish to keep the topic off the agenda at the Commonwealth Heads of Government Meeting. Buckingham Palace announces that Charles III is expected to return to a "normal" schedule in 2025 after his trip to the Commonwealth summit proved to be a "perfect tonic". A video emerges that appears to show Mike Amesbury, the MP for Runcorn and Helsby, shouting and swearing at a man who is lying on the ground during an apparent disturbance. Secretary of State for Wales Jo Stevens is accused by the Conservatives of bringing her office into disrepute after recording a political interview on its premises, something which they say breaches the civil service code. 28 October – The speaker of the House of Commons, Lindsay Hoyle, reprimands the chancellor, Rachel Reeves, in the Commons for giving information to journalists in the US about the upcoming Budget, in potential contravention of the ministerial code, which expects major government announcements to be made in the Commons before to the news media.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.